These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 9383724)

  • 1. Individual and average bioequivalence of highly variable drugs and drug products.
    Midha KK; Rawson MJ; Hubbard JW
    J Pharm Sci; 1997 Nov; 86(11):1193-7. PubMed ID: 9383724
    [No Abstract]   [Full Text] [Related]  

  • 2. On TIER method for assessment of individual bioequivalence.
    Ju HL
    J Biopharm Stat; 1997 Mar; 7(1):63-85. PubMed ID: 9056589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Individual bioequivalence--a European perspective.
    Steinijans VW; Hauschke D
    J Biopharm Stat; 1997 Mar; 7(1):31-4. PubMed ID: 9056585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of average, scaled average, and population bioequivalence methods for assessment of highly variable drugs: an experience with doxifluridine in beagle dogs.
    Baek IH; Lee BY; Kang W; Kwon KI
    Eur J Pharm Sci; 2010 Jan; 39(1-3):175-80. PubMed ID: 19961933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A method for the evaluation of individual bioequivalence.
    Endrenyi L
    Int J Clin Pharmacol Ther; 1994 Sep; 32(9):497-508. PubMed ID: 7820334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generic products of antiepileptic drugs: a perspective on bioequivalence and interchangeability.
    Bialer M; Midha KK
    Epilepsia; 2010 Jun; 51(6):941-50. PubMed ID: 20384761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extension to the use of tolerance intervals for the assessment of individual bioequivalence.
    Esinhart JD; Chinchilli VM
    J Biopharm Stat; 1994 Mar; 4(1):39-52. PubMed ID: 8019583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Types of bioequivalence and related statistical considerations.
    Hauck WW; Anderson S
    Int J Clin Pharmacol Ther Toxicol; 1992 May; 30(5):181-7. PubMed ID: 1592546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The transitivity of bioequivalence testing: potential for drift.
    Anderson S; Hauck WW
    Int J Clin Pharmacol Ther; 1996 Sep; 34(9):369-74. PubMed ID: 8880284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viewpoint: observations on scaled average bioequivalence.
    Patterson SD; Jones B
    Pharm Stat; 2012; 11(1):1-7. PubMed ID: 22162308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current challenges facing the determination of product bioequivalence in veterinary medicine.
    Martinez MN; Hunter RP
    J Vet Pharmacol Ther; 2010 Oct; 33(5):418-33. PubMed ID: 20840385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating product bioequivalence for highly variable veterinary drugs.
    Claxton R; Cook J; Endrenyi L; Lucas A; Martinez MN; Sutton SC
    J Vet Pharmacol Ther; 2012 Apr; 35 Suppl 1():11-6. PubMed ID: 22413787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conference report: Bio-International 2005.
    Midha KK; Shah VP; Singh GJ; Patnaik R
    J Pharm Sci; 2007 Apr; 96(4):747-54. PubMed ID: 17094144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing bioequivalence using genomic data.
    Chow SC; Shao J; Li L
    J Biopharm Stat; 2004 Nov; 14(4):869-80. PubMed ID: 15587969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discussion of individual bioequivalence by M.-L. Chen.
    Gould AL
    J Biopharm Stat; 1997 Mar; 7(1):23-9. PubMed ID: 9056584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
    Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Innovative approaches for demonstration of bioequivalence: the US FDA perspective.
    Zhang X; Zheng N; Lionberger RA; Yu LX
    Ther Deliv; 2013 Jun; 4(6):725-40. PubMed ID: 23738669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation on the need of multiple dose bioequivalence studies for prolonged-release generic products.
    García-Arieta A; Morales-Alcelay S; Herranz M; de la Torre-Alvarado JM; Blázquez-Pérez A; Suárez-Gea ML; Alvarez C
    Int J Pharm; 2012 Feb; 423(2):321-5. PubMed ID: 22120644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A limited sampling approach in bioequivalence studies: application to long half-life drugs and replicate design studies.
    Mahmood I; Mahayni H
    Int J Clin Pharmacol Ther; 1999 Jun; 37(6):275-81. PubMed ID: 10395118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishing bioequivalence for inhaled drugs; weighing the evidence.
    Daley-Yates PT; Parkins DA
    Expert Opin Drug Deliv; 2011 Oct; 8(10):1297-308. PubMed ID: 21699442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.